We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

136 hedge funds and large institutions have $2.34B invested in MoonLake Immunotherapeutics in 2025 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 33 increasing their positions, 43 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

141% more call options, than puts

Call options by funds: $21.1M | Put options by funds: $8.78M

140% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 15

18% more funds holding

Funds holding: 115 → 136 (+21)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

5.92% less ownership

Funds ownership: 100.57% → 94.65% (-5.9%)

23% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 43

32% less capital invested

Capital invested by funds: $3.43B → $2.34B (-$1.09B)

Holders
136
Holders Change
+21
Holders Change %
+18.26%
% of All Funds
1.82%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
36
Increased
33
Reduced
43
Closed
15
Calls
$21.1M
Puts
$8.78M
Net Calls
+$12.3M
Net Calls Change
+$9.63M

Top Buyers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
+$15.1M
2
Millennium Management
Millennium Management
New York
+$14.8M
3
OCA
Octagon Capital Advisors
New York
+$12.8M
4
VPC
Vestal Point Capital
New York
+$8.62M
5
Franklin Resources
Franklin Resources
California
+$8.25M

Top Sellers

Rank Fund Capital Flow
1
Holocene Advisors
Holocene Advisors
New York
-$60.2M
2
PBA
Paradigm Biocapital Advisors
New York
-$49.3M
3
Citadel Advisors
Citadel Advisors
Florida
-$30.5M
4
Marshall Wace
Marshall Wace
United Kingdom
-$26M
5
EC
EcoR1 Capital
California
-$18M
Name Holding Trade Value Shares
Change 		Change in
Stake
OCA
26
Octagon Capital Advisors
New York
$11.6M +$12.8M +296,000 New
BlackRock
27
BlackRock
New York
$11.2M -$3.56M -82,636 -22%
5VM
28
5AM Venture Management
California
$11M – – –
Victory Capital Management
29
Victory Capital Management
Texas
$10.1M +$3.43M +79,649 +45%
TD Asset Management
30
TD Asset Management
Ontario, Canada
$8.47M -$1.93M -44,730 -17%
Ameriprise
31
Ameriprise
Minnesota
$7.87M -$123K -2,852 -1%
IHAM
32
Integral Health Asset Management
New York
$7.81M – – –
VPC
33
Vestal Point Capital
New York
$7.81M +$8.62M +200,000 New
Franklin Resources
34
Franklin Resources
California
$7.48M +$8.25M +191,500 New
Holocene Advisors
35
Holocene Advisors
New York
$7.38M -$60.2M -1,396,178 -88%
FTM
36
First Turn Management
California
$7M +$7.72M +179,196 New
CS
37
Candriam SCA
Luxembourg
$6.82M -$2.28M -52,956 -23%
DC
38
Decheng Capital
California
$6.7M – – –
GIM
39
Granahan Investment Management
Massachusetts
$5.56M +$249K +5,782 +4%
RHJA
40
Rice Hall James & Associates
California
$5.37M +$1.14M +26,383 +24%
Manulife (Manufacturers Life Insurance)
41
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4.88M -$767K -17,798 -12%
UBS Group
42
UBS Group
Switzerland
$4.72M +$4M +92,851 +333%
CCM
43
Catalio Capital Management
New York
$4.48M +$4.94M +114,616 New
Vanguard Group
44
Vanguard Group
Pennsylvania
$4.45M -$60.2K -1,398 -1%
Axa
45
Axa
France
$4.06M -$5.77K -134 -0.1%
HCA
46
Harbor Capital Advisors
Illinois
$3.99M +$964K +22,372 +28%
State Street
47
State Street
Massachusetts
$3.65M +$79.8K +1,852 +2%
Bank of America
48
Bank of America
North Carolina
$3.56M +$1.97M +45,634 +100%
Hudson Bay Capital Management
49
Hudson Bay Capital Management
Connecticut
$3.13M +$3.12M +72,500 +967%
Balyasny Asset Management
50
Balyasny Asset Management
Illinois
$3.08M -$5.5M -127,733 -62%
1
2
3 4 5

MLTX Hedge Fund Activity: Q1 2025 in Review

136 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q1 2025, worth a combined $2.34B — down 32% from $3.43B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new MLTX positions and 15 closed out — a net gain of 21 holders — while 33 added to existing stakes and 43 trimmed.

The largest buyer was Logos Global Management, opening a new position worth an estimated $15.1M. The largest seller was Holocene Advisors, cutting an estimated $60.2M.

  • 136 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q1 2025, up from 115 in Q4 2024.
  • Funds reported $2.34B of MoonLake Immunotherapeutics stock for Q1 2025, down 32% quarter-over-quarter.
  • 36 funds opened new MoonLake Immunotherapeutics positions in Q1 2025 and 15 closed out, a net change of +21 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q1 2025 was Logos Global Management, an estimated $15.1M added.
  • The largest MoonLake Immunotherapeutics seller in Q1 2025 was Holocene Advisors, an estimated $60.2M sold.

Based on aggregated 13F filings for Q1 2025.